" Metastatic Melanoma Pipeline Insight, 2024 " report by DelveInsight outlines comprehensive insights into the current clinical development scenario and growth prospects across the Metastatic Melanoma Market.
The Metastatic Melanoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities including the technology, collaborations, acquisition mergers, funding, designations, and other product-related details.
Some of the key takeaways from the Metastatic Melanoma Pipeline Report:
- Companies across the globe are diligently working towards developing novel Metastatic Melanoma treatment therapies with a considerable amount of success over the years.
- Metastatic Melanoma companies working in the treatment market are TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics , and others, are developing therapies for the Metastatic Melanoma treatment
- Emerging Metastatic Melanoma therapies in the different phases of clinical trials are- TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others are expected to have a significant impact on the Metastatic Melanoma market in the coming years.
- In April 2024, Obsidian Therapeutics shared an update on its Phase I first-in-human trial of OBX-115 tumor-infiltrating lymphocyte (TIL) cell therapy for advanced or metastatic melanoma. The update, presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, included 25-week median follow-up safety data and newly detailed efficacy findings.
- In April 2024, Iovance Biotherapeutics revealed that clinical data on lifileucel combined with pembrolizumab for frontline advanced melanoma, along with translational findings, will be featured at the 2024 ASCO Annual Meeting.
- In December 2023, Obsidian Therapeutics reported positive top-line results from its ongoing Phase 1 first-in-human trial assessing the safety and efficacy of OBX-115, its lead-engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced or metastatic melanoma following anti-PD1 therapy.
Metastatic Melanoma Overview
Metastatic Melanoma is an advanced stage of melanoma, a type of skin cancer, where cancer cells spread beyond the original tumor site to distant organs such as the lungs, liver, brain, or bones. It occurs when melanoma cells invade the bloodstream or lymphatic system, leading to secondary tumors. Metastatic melanoma is highly aggressive but can be treated with targeted therapies (BRAF and MEK inhibitors), immunotherapy (checkpoint inhibitors like nivolumab and pembrolizumab), chemotherapy, or radiation therapy. Early detection and advanced treatments have improved survival rates and patient outcomes.
Get a Free Sample PDF Report to know more about Metastatic Melanoma Pipeline Therapeutic Assessment:
https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight
Emerging Metastatic Melanoma Drugs Under Different Phases of Clinical Development Include:
- TILT 123: TILT Biotherapeutics
- AV-MEL-1: AiVita Biomedical
- IMM-1-104: Immuneering Corporation
- UV1: Ultimovacs ASA
- APX005: MPyxis Oncology
- EVX 01: Evaxion Biotech
- HBI-8000: HUYABIO International, LLC.
- IO102-IO103: IO Biotech
- Fianlimab: Regeneron Pharmaceuticals
Metastatic Melanoma Route of Administration
Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Metastatic Melanoma Molecule Type
Metastatic Melanoma Products have been categorized under various Molecule types, such as
- Oligonucleotide
- Peptide
- Small molecule
Metastatic Melanoma Pipeline Therapeutics Assessment
- Metastatic Melanoma Assessment by Product Type
- Metastatic Melanoma By Stage and Product Type
- Metastatic Melanoma Assessment by Route of Administration
- Metastatic Melanoma By Stage and Route of Administration
- Metastatic Melanoma Assessment by Molecule Type
- Metastatic Melanoma by Stage and Molecule Type
DelveInsight's Metastatic Melanoma Report covers around 75+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued Inactive candidates
- Route of Administration
Further Metastatic Melanoma product details are provided in the report. Download the Metastatic Melanoma pipeline report to learn more about the emerging Metastatic Melanoma therapies
Some of the key companies in the Metastatic Melanoma Therapeutics Market include:
Key companies developing therapies for Metastatic Melanoma are - Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, Biocad, Apexigen, Checkmate Pharmaceutical, Nektar therapeutics, HUYABIO International, LLC., IO Biotech, Bristol Myers Squibb, Karyopharm Therapeutics, Zucero Therapeutics, GlaxoSmithKline, Tesaro, Inc., Ultimovacs ASA, Eucure (Beijing) Biopharma Co., Ltd, Incyte Corporation, Philogen S.p.A., Ascentage Pharma, Exelixis/Ipsen, NovoCure Ltd., Hoffman-La-Roche, Provectus Biopharmaceuticals, BerGenBio ASA, Idera Pharmaceuticals, Celgene Corporation, Novartis, Taizhou Hanzhong biomedical co. LTD, Scancell Ltd, BioMed Valley Discoveries, Inc., Nykode Therapeutics, Sapience Therapeutics, BeiGene, Immunocore, Achilles Therapeutics UK Limited, Vanquish Oncology, Syntrix Biosystems, Inc., TILT Biotherapeutics, PrimeVax Immuno-Oncology Inc., Celldex Therapeutics, Taiga Biotechnologies, Inc., Galectin Therapeutics Inc, Foghorn Therapeutics Inc., TriSalus Life Sciences, Inc., Miltenyi Biomedicine GmbH, CytomX Therapeutics, Inc., Seagen Inc., Immutep, Regeneron pharmaceuticals, Adaptimmune, IDEAYA Biosciences, PokeAcell, Ultimovacs ASA, Verastem, Inc., PACT Pharma, Actuate Therapeutics, Inc., and others.
Metastatic Melanoma Pipeline Analysis:
The Metastatic Melanoma pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Melanoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Melanoma Treatment.
- Metastatic Melanoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Melanoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Metastatic Melanoma drugs and therapies
Metastatic Melanoma Pipeline Market Drivers
- Improving Healthcare Infrastructure, emergence of effective immune therapies are some of the important factors that are fueling the Metastatic Melanoma Market.
Metastatic Melanoma Pipeline Market Barriers
- However, lack Of Cost-Effective Treatment, side effects associated with the treatment and other factors are creating obstacles in the Metastatic Melanoma Market growth.
Scope of Metastatic Melanoma Pipeline Drug Insight
- Coverage: Global
- Key Metastatic Melanoma Companies: TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others
- Key Metastatic Melanoma Therapies: TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others
- Metastatic Melanoma Therapeutic Assessment: Metastatic Melanoma current marketed and Metastatic Melanoma emerging therapies
- Metastatic Melanoma Market Dynamics: Metastatic Melanoma market drivers and Metastatic Melanoma market barriers
Request for Sample PDF Report for Metastatic Melanoma Pipeline Assessment and clinical trials
Table of Contents
- Metastatic Melanoma Report Introduction
- Metastatic Melanoma Executive Summary
- Metastatic Melanoma Overview
- Metastatic Melanoma- Analytical Perspective In-depth Commercial Assessment
- Metastatic Melanoma Pipeline Therapeutics
- Metastatic Melanoma Late Stage Products (Phase II/III)
- Metastatic Melanoma Mid Stage Products (Phase II)
- Metastatic Melanoma Early Stage Products (Phase I)
- Metastatic Melanoma Preclinical Stage Products
- Metastatic Melanoma Therapeutics Assessment
- Metastatic Melanoma Inactive Products
- Company-University Collaborations (Licensing/Partnering) Analysis
- Metastatic Melanoma Key Companies
- Metastatic Melanoma Key Products
- Metastatic Melanoma Unmet Needs
16 . Metastatic Melanoma Market Drivers and Barriers
- Metastatic Melanoma Future Perspectives and Conclusion
- Metastatic Melanoma Analyst Views
- Appendix
- About DelveInsight
Related Reports:
Metastatic Melanoma Market https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight?utm_source=pressreleaseutm_medium=promotionutm_campaign=akpr
DelveInsight’s ‘Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom).
Latest Reports:
Telemedicine Service Market https://www.delveinsight.com/report-store/telemedicine-service-market
Telemedicine Service Market By Service Type (Tele Consulting And Tele Monitoring), By Application (Telepathology, Telecardiology, Teleradiology, Teledermatology, Telepsychiatry, Other Services), By End-User (Healthcare Facilities And Homecare), by geography, is projected to grow at a significant CAGR forecast till 2028 owing to the sudden outbreak of covid-19 pandemic and shifting focus for reducing the burden of healthcare cost
Wearable Medical Devices Market https://www.delveinsight.com/report-store/wearable-medical-devices-market
Wearable Medical Devices Market By Device Type (Diagnostic And Monitoring Devices [Vital Sign Monitoring Devices, Sleep Monitoring Devices, Electrocardiographs Fetal And Obstetric Devices, Neuromonitoring Devices, And Others] And Therapeutic Devices [Pain Management Devices, Rehabilitation Devices, Respiratory Therapy Devices, And Others]), By Product Type (Wristband, Headband, Ear Wear, Watch, And Others), By Application (Sports And Fitness, Remote Patient Monitoring, And Home Healthcare), By Distribution Channel (Online And Offline), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to a rise in the geriatric population and increasing prevalence of chronic diseases across the globe.
Surgical Robotic System Market https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical Robotic Systems Market By Application (Urology, Gynecology, Neurosurgery, Orthopedics, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), And by geography is estimated to register appreciable CAGR forecast until 2028 owing to increase in surgical procedures and rising popularity of minimally invasive surgical interventions.
https://www.delveinsight.com/report-store/cancer-diagnostic-market
Cancer Diagnostics Market By Type (Product Type [Reagent Kits and Instruments], and Services), Technique (Molecular Diagnostics [Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH), Microarray, and Immunohistochemistry], Diagnostics Imaging [Ultrasound Radiology, Mammography, MRI Scan, CT Scan, and Nuclear Medicine Scans], Endoscopy, and Biopsy [Standard Biopsy and Liquid Biopsy]), Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, and Others), End-User (Hospitals, Diagnostics Labs, and Others), and Geography, is expected to grow at a significant CAGR forecast until 2028 owing to the growing burden of cancer across the globe and rise in various product launches for efficient detection of cancer.
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast until 2028 owing to the availability of advanced devices and increasing prevalence of respiratory diseases such as COPD.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us:
Abhishek Kumar
abhishek@delveinsight.com
+91-9650213330
